Oruka Therapeutics (NASDAQ:ORKA) Hits New 12-Month High After Earnings Beat

Oruka Therapeutics, Inc. (NASDAQ:ORKA) reached a new 52-week high on Friday after the company announced better than expected quarterly earnings. The stock traded as high as $38.75 and last traded at $38.6030, with a volume of 220537 shares traded. The stock had previously closed at $31.99.

The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.16.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. BTIG Research raised their target price on shares of Oruka Therapeutics from $63.00 to $73.00 and gave the stock a “buy” rating in a report on Monday, January 12th. UBS Group initiated coverage on shares of Oruka Therapeutics in a report on Wednesday, January 7th. They set a “buy” rating and a $50.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Thursday, January 22nd. Piper Sandler assumed coverage on shares of Oruka Therapeutics in a research note on Thursday, December 18th. They issued an “overweight” rating and a $75.00 price objective for the company. Finally, Wedbush reaffirmed an “outperform” rating and set a $45.00 target price on shares of Oruka Therapeutics in a research note on Friday. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Oruka Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $56.44.

Insider Activity

In other news, insider Joana Goncalves sold 7,000 shares of the business’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $32.37, for a total transaction of $226,590.00. Following the completion of the sale, the insider directly owned 34,018 shares of the company’s stock, valued at approximately $1,101,162.66. The trade was a 17.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 21,000 shares of company stock worth $663,530 over the last ninety days. 24.69% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Oruka Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Financial Enhancement Group LLC bought a new position in Oruka Therapeutics in the 3rd quarter worth about $631,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management purchased a new position in shares of Oruka Therapeutics during the third quarter worth approximately $296,000. B Group Inc. raised its stake in shares of Oruka Therapeutics by 28.8% during the second quarter. B Group Inc. now owns 75,000 shares of the company’s stock valued at $841,000 after acquiring an additional 16,785 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Oruka Therapeutics by 100.6% during the second quarter. Geode Capital Management LLC now owns 707,406 shares of the company’s stock valued at $7,932,000 after acquiring an additional 354,821 shares in the last quarter. Finally, Affinity Asset Advisors LLC boosted its holdings in shares of Oruka Therapeutics by 10.7% in the second quarter. Affinity Asset Advisors LLC now owns 603,479 shares of the company’s stock valued at $6,765,000 after purchasing an additional 58,117 shares during the period. Institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Price Performance

The stock has a market cap of $1.84 billion, a PE ratio of -19.90 and a beta of -0.38. The business has a fifty day moving average of $32.68 and a 200-day moving average of $27.32.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.